OCUGEN, INC. Proceeds from Issuance or Sale of Equity
OCUGEN, INC. (OCGN) reported Proceeds from Issuance or Sale of Equity of $18.33 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2025-11-05
- OCUGEN, INC. proceeds from issuance or sale of equity for the quarter ending 2019-09-30 was -$168.00.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month |
|---|---|---|---|
| 2025-09-30 | $18.33M 10-Q · filed 2025-11-05 | ||
| 2024-09-30 | $37.58M 10-Q · filed 2025-11-05 | ||
| 2019-09-30 | -$168.00 derived: 10-Q 9 month − 8-K/A 6 month · filed 2019-11-12 | $999.83K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $1.00M 8-K/A · filed 2019-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |